Avenue Therapeutics reports Q3 EPS $(1.92) , consensus (94c)

As of September 30 cash and cash equivalents totaled $2.6M , compared to $4.9M at June 30 and $1.8 M at December 31, 2023, a decrease of $2.3M compared to the prior quarter and an increase of $0.8M year-to-date..”We have generated considerable momentum this past quarter in advancing our pipeline of innovative treatments for neurologic diseases,” said Alexandra MacLean, M.D., Chief Executive Officer of Avenue. “AJ201 is a potential best-in-class asset that would bring a disease-modifying therapeutic option to patients with significant unmet medical need in Kennedy’s Disease. Since dosing the last patient in the study in May, we continue to work diligently to move the study forward. We are looking forward to sharing topline clinical data in the coming months and building upon our progress of delivering impactful therapies to patients suffering from neurologic diseases.”